Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Rhea-AI Summary

Editas Medicine (Nasdaq: EDIT) reported Q4 and full-year 2025 results and business updates on March 9, 2026. Key highlights: EDIT-401 showed >90% mean LDL-C reduction in preclinical non-human primates and remains on track for an IND/CTA submission by mid-2026 and first-in-human dosing later in 2026. Cash and cash equivalents were $146.6M as of Dec 31, 2025, with a projected runway into Q3 2027. Full-year net loss was $160.1M (EPS -$1.80). The company expects early human proof-of-concept data by year-end 2026 and topline dose-finding results in 2027.

Positive

• Lead candidate EDIT-401 showed >90% mean LDL-C reduction in preclinical studies
• Cash balance of $146.6M provides runway into the third quarter of 2027
• Collaboration and R&D revenue increased to $40.5M for full-year 2025

Negative

• Full-year net loss of $160.1M (2025) reflecting continued operating losses
• Research and development expense decreased to $90.0M, reflecting program cuts
• Restructuring and impairment charges rose to $60.7M in 2025

Key Figures

LDL-C reduction: >90% mean LDL-C reduction IND/CTA timing: Mid-2026 Human proof-of-concept: Year-end 2026 +5 more

8 metrics

LDL-C reduction >90% mean LDL-C reduction EDIT-401 preclinical studies in non-human primates

IND/CTA timing Mid-2026 Planned IND/CTA submission for EDIT-401

Human proof-of-concept Year-end 2026 Target for early human proof-of-concept data in HeFH trial

Cash balance $146.6M Cash and cash equivalents as of Dec 31, 2025

Cash runway Into Q3 2027 Management guidance based on current cash position

Q4 2025 net loss $5.6M ($0.06/share) Three months ended Dec 31, 2025

FY 2025 net loss $160.1M ($1.80/share) Full year 2025

R&D expenses 2025 $90.0M Down from $199.2M in 2024, reflecting program discontinuation

Market Reality Check

Price: $2.32 Vol: Volume 2,263,574 is 40% a...

normal vol

$2.32 Last Close

Volume Volume 2,263,574 is 40% above the 20-day average of 1,613,949, indicating elevated interest into earnings. normal

Technical Shares at $2.00 are trading below the 200-day MA at $2.53, despite today’s gain.

Peers on Argus

EDIT is up 5.54% with sector peers also positive (e.g., SLN +14.52%, PRQR +7.23%...

EDIT is up 5.54% with sector peers also positive (e.g., SLN +14.52%, PRQR +7.23%). However, momentum scanners did not flag a coordinated sector move, suggesting a more stock-specific reaction to earnings.

Previous Earnings Reports

5 past events · Latest: Nov 10 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 10	Q3 2025 earnings	Positive	+2.0%	Improved loss profile, EDIT-401 data, and extended cash runway into Q3 2027.
Aug 12	Q2 2025 earnings	Positive	+34.5%	Narrowed net loss, strong cash position, and clear in vivo development timeline.
May 12	Q1 2025 earnings	Negative	-2.6%	Larger quarterly loss and sizable restructuring charges despite solid cash runway.
Mar 05	FY 2024 earnings	Negative	-13.2%	Significant full-year loss and major workforce reduction during strategic refocus.
Nov 04	Q3 2024 earnings	Negative	-1.0%	Large net loss and revenue decline alongside early in vivo proof-of-concept data.

Pattern Detected

Earnings updates have typically produced price moves in the low- to mid-single digits, with reactions generally aligning with the tone of operational progress and cost reductions.

Recent Company History

Across recent earnings releases from Nov 2024 through Nov 2025, Editas has steadily shifted focus to in vivo gene editing while narrowing losses and extending cash runway into 2027. Net losses have trended lower versus 2024 levels, supported by reduced R&D and restructuring tied to the former reni-cel program. The current Q4/FY25 update continues this pattern, highlighting EDIT-401 progress and a maintained runway into Q3 2027.

Historical Comparison

+3.9% avg move · In the past year, EDIT’s earnings updates moved the stock an average of 3.94%. Today’s 5.54% gain is...

earnings

+3.9%

Average Historical Move earnings

In the past year, EDIT’s earnings updates moved the stock an average of 3.94%. Today’s 5.54% gain is somewhat larger but still broadly consistent with prior earnings reactions.

Successive earnings reports show a transition away from the reni-cel program, lower operating expenses, and a growing emphasis on EDIT-401 and in vivo gene editing milestones.

Market Pulse Summary

This announcement combines detailed Q4 and full-year 2025 financials with clear timelines for EDIT-4...

Analysis

This announcement combines detailed Q4 and full-year 2025 financials with clear timelines for EDIT-401, including an IND/CTA by mid-2026 and early human proof-of-concept by year-end 2026. Cash of $146.6M and runway into Q3 2027 frame the development window. Investors may watch how net loss of $160.1M, reduced R&D spending, and progress toward first-in-human HeFH studies evolve over coming quarters.

Key Terms

ldl-c, ind/cta, first-in-human, proof-of-concept, +2 more

6 terms

ldl-c medical

"demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track"

LDL-C stands for low-density lipoprotein cholesterol, the portion of cholesterol carried in the blood by LDL particles that is commonly linked to buildup of plaque in arteries—think of it like sticky debris that can clog pipes. Investors care because changes in LDL-C are a key measure used by regulators and clinicians to judge the effectiveness of cardiovascular drugs and devices, shape insurance coverage, and influence market demand for treatments that lower heart attack and stroke risk.

ind/cta regulatory

"remains on track for IND/CTA submission by mid-2026 Preparing to initiate"

An IND/CTA is a formal regulatory submission that asks health authorities for permission to test an experimental drug or treatment in humans — IND is the U.S. route, CTA is the equivalent in many other countries. Think of it as the safety permit a developer must obtain before starting human trials; investors watch these filings because approval clears a major regulatory hurdle, changes development timelines and risk, and can materially affect a program’s value and funding needs.

first-in-human medical

"Preparing to initiate Company’s first-in-human clinical trial in HeFH patients"

A first-in-human study is the initial test of a new drug, medical device, or therapy in people to check safety, side effects and appropriate dosing. It matters to investors because it marks a major development milestone: successful early human testing can reduce scientific and regulatory uncertainty, much like moving a prototype from the workshop to a real-world test drive, and often affects a company’s valuation and funding prospects.

proof-of-concept medical

"with early human proof-of-concept data on track for year-end 2026"

A proof-of-concept is a demonstration that shows a new idea or method can work as intended, serving as a small-scale test before full development. For investors, it signals that a concept has been successfully tested in principle, reducing uncertainty about whether it can be practically implemented. This helps determine if further investment or effort is justified to develop the idea further.

in vivo medical

"we advanced our mission and strategy to become a leader in in vivo gene editing"

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.

non-human primates medical

"more than 90 percent in non-human primates, and will present additional"

Non-human primates are members of the primate family other than people — such as monkeys and apes — that are used in biomedical research because their biology is closer to humans than rodents. For investors, results from studies in these animals can strongly influence a drug or vaccine’s safety profile, development timeline, regulatory chances and costs, acting like a high-fidelity dress rehearsal before human clinical trials.

AI-generated analysis. Not financial advice.

Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 

Preparing to initiate Company’s first-in-human clinical trial in HeFH patients, with early human proof-of-concept data on track for year-end 2026

Strong cash position with cash runway into the third quarter of 2027

CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2025 and provided business updates.

“We achieved notable progress in the fourth quarter of 2025 as we advanced our mission and strategy to become a leader in in vivo gene editing,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. “We continue to advance our lead in vivo development candidate, EDIT-401, an experimental, potential best-in-class, one-time therapy, which demonstrated significantly reduced mean LDL cholesterol levels of over 90 percent in preclinical studies. With cash runway into the third quarter of 2027, we are in a strong position to drive EDIT-401 toward upcoming milestones and look forward to submitting an IND/CTA by mid-2026 and initiating our first-in-human trial of EDIT-401 in patients living with heterozygous familial hypercholesterolemia (HeFH) later this year.”

Recent Achievements and Upcoming Milestones

• Editas continues to advance its lead in vivo development candidate, EDIT-401, which has demonstrated the potential to reduce mean LDL cholesterol levels by more than 90 percent in non-human primates, and will present additional preclinical data by mid-2026.
• The Company remains on track to submit an IND/CTA for EDIT-401 by mid-2026.
• Editas is preparing to initiate a first-in-human clinical trial in patients with HeFH later this year, and the Company is on track to achieve early human proof-of-concept data by the end of 2026.
• Editas plans to complete enrolling the dose-finding portion of the first-in-human clinical trial with topline data results available in 2027.
  
  

Upcoming Events

Editas Medicine plans to participate in the following investor event:

• Barclays 28th Annual Global Healthcare Conference
  Format: Fireside Chat
  Date: March 12, 2026
  Time: 8:30 a.m. ET
  Miami Beach, FL
  
  

To access a live webcast of the investor presentation, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the event.

Fourth Quarter and Full Year 2025 Financial Results
Cash and cash equivalents as of December 31, 2025, were $146.6 million compared to $269.9 million as of December 31, 2024. The Company expects that the existing cash and cash equivalents will enable the Company to fund its operating expenses and capital expenditure requirements into the third quarter of 2027.

Fourth Quarter 2025

• For the three months ended December 31, 2025, net loss attributable to common stockholders was $5.6 million, or $0.06 per share, compared to net loss of $45.4 million, or $0.55 per share, for the same period in 2024.

• Collaboration and other research and development revenues decreased to $24.7 million for the three months ended December 31, 2025, compared to $30.6 million for the same period in 2024. The decrease is primarily attributable to the recognition of revenue related to milestones achieved under the Company’s collaboration agreement with BMS in the fourth quarter of 2024.

• Research and development expenses decreased by $21.2 million to $27.4 million for the three months ended December 31, 2025, compared to $48.6 million for the same period in 2024. The decrease is primarily related to reduced clinical and manufacturing costs related to discontinuation of the clinical development of the Company’s reni-cel program initiated in December 2024, partially offset by costs attributable to in vivo research and discovery.

• General and administrative expenses decreased by $5.0 million to $11.4 million for the three months ended December 31, 2025, compared to $16.4 million for the same period in 2024. The decrease is primarily attributable to a reduction in employee-related expenses related to reduced headcount associated with the reduction in workforce, as well as reduced professional services in connection with the discontinuation of the clinical development of the Company’s reni-cel program initiated in December 2024.

• Restructuring and impairment charges decreased by $18.5 million to a $6.3 million benefit for the three months ended December 31, 2025, compared to $12.2 million for the same period in 2024. The decrease is primarily attributable to favorable adjustments to prior estimated costs for contracts associated with the discontinuation of the clinical development of the Company’s reni-cel program upon finalization of contract costs.
  
  

Full Year 2025

• For the full year 2025, net loss attributable to common stockholders was $160.1 million, or $1.80 per share, compared to net loss of $237.1 million, or $2.88 per share, for the same period in 2024.

• Collaboration and other research and development revenues increased to $40.5 million for 2025, compared to $32.3 million for the same period in 2024. The increase was attributable to recognition of the remaining deferred revenue upon the conclusion of a collaboration agreement with a strategic partner, as well as recognition of revenue related to a milestone achieved in 2025 under our collaboration with BMS.

• Research and development expenses decreased by $109.2 million to $90.0 million for 2025, compared to $199.2 million for the same period in 2024. The decrease was primarily attributable to reduced clinical and manufacturing costs due to the discontinuation of the Company’s former reni-cel program, partially offset by costs attributable to in vivo research and discovery.

• General and administrative expenses decreased by $22.1 million to $49.9 million for 2025, compared to $72.0 million for the same period in 2024. The decrease was primarily related to reduced headcount associated with the workforce reduction and reduced professional services related to the discontinuation of the Company’s former reni-cel program.

• Restructuring and impairment charges increased by $48.4 million to $60.7 million for 2025, compared to $12.2 million for the same period in 2024. The increase was attributable actions associated with the discontinuation of the Company’s former reni-cel program and the associated workforce reduction.
  
  

About Heterozygous Familial Hypercholesterolemia (HeFH)
Heterozygous Familial Hypercholesterolemia (HeFH) is an inherited genetic disorder that leads to significantly elevated LDL‑cholesterol levels from an early age. Individuals with HeFH are at high risk of heart disease, heart attack, or stroke if the condition is not identified and treated early. An estimated 1.2 million people in the United States are living with HeFH, though many remain undiagnosed. Elevated LDL-C, also known as hyperlipidemia, is a highly prevalent disease affecting over 70 million patients in the United States alone. Substantial unmet need exists across multiple at-risk segments of patients with hyperlipidemia, including the HeFH population.

About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the initiation, timing, progress and results of the Company’s preclinical studies and planned clinical trials, including the Company’s expectation to achieve early human proof-of-concept data for EDIT-401 by year-end 2026 and complete enrolling the dose-finding portion of the EDIT-401 clinical trial with topline data results available in 2027; the timing for the Company’s receipt and presentation of data from its preclinical studies, including presenting additional preclinical data for EDIT-401 by mid-2026; the potential of, and expectations for, EDIT-401 and the Company’s other future in vivo product candidates; the timing or likelihood of regulatory submissions and approvals, including the timing of submission of an IND/CTA for EDIT-401 by mid-2026; and the Company’s expectations regarding its cash runway and the milestones that can be achieved with that cash runway. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation, timing, progress, and results of preclinical studies and clinical trials; uncertainty regarding availability and timing of results from preclinical studies and clinical trials; uncertainties relating to planned regulatory submissions to initiate clinical trials, including that results of preclinical studies will warrant such submissions or that regulatory agencies may require additional preclinical studies, that regulatory submissions shall occur on the expected timelines and that regulatory authorities will provide clearance for trials to be initiated; and that the Company will not be able to raise funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

EDITAS MEDICINE, INC. Consolidated Statement of Operations (amounts in thousands, except share and per share data) (Unaudited)
		Three Months Ended December 31,								Twelve Months Ended December 31,
			2025				2024				2025				2024
Collaboration and other research and development revenues		$	24,741			$	30,604			$	40,520			$	32,314
Operating expenses:
Research and development			27,404				48,611				89,953				199,247
General and administrative			11,353				16,354				49,903				71,987
Restructuring charges			(6,261	)			12,232				60,674				12,232
Total operating expenses			32,496				77,197				200,530				283,466
Operating loss			(7,755	)			(46,593	)			(160,010	)			(251,152	)
Other income (expense), net:
Interest expense related to sale of future revenues			464				(2,190	)			(6,171	)			(2,190	)
Interest income, net			1,676				3,391				8,310				16,252
Other expense, net			(5	)			(3	)			(2,189	)			(3	)
Total other income (expense), net			2,135				1,198				(50	)			14,059
Net loss		$	(5,620	)		$	(45,395	)		$	(160,060	)		$	(237,093	)
Net loss per share, basic and diluted		$	(0.06	)		$	(0.55	)		$	(1.80	)		$	(2.88	)
Weighted-average common shares outstanding, basic and diluted			97,255,149				82,613,831				88,745,908				82,338,220

EDITAS MEDICINE, INC. Selected Consolidated Balance Sheet Items (amounts in thousands) (Unaudited)
		December 31,				December 31,
			2025				2024
Cash, cash equivalents, and marketable securities		$	146,645			$	269,913
Working capital			117,649				212,090
Total assets			186,534				341,589
Deferred revenue, net of current portion			44,509				54,204
Total stockholders' equity			27,288				134,274

Investor and Media Contacts:
ir@editasmed.com
media@editasmed.com

FAQ

What cash runway did Editas Medicine (EDIT) report on March 9, 2026?

Editas reported $146.6 million in cash and equivalents, with runway into the third quarter of 2027. According to the company, this balance is expected to fund operating expenses and capital requirements through Q3 2027, supporting planned IND/CTA and early clinical work.

When will Editas (EDIT) submit an IND/CTA for EDIT-401 and begin first-in-human dosing?

Editas expects to submit an IND/CTA by mid-2026 and initiate first-in-human dosing later in 2026. According to the company, early human proof-of-concept data is targeted by year-end 2026, with dose-finding topline results anticipated in 2027.

How did Editas (EDIT) perform financially for full-year 2025?

Editas reported a full-year net loss of $160.1 million, or $1.80 per share, for 2025. According to the company, collaboration and R&D revenues rose to $40.5 million, while R&D and G&A expenses declined due to program discontinuations and workforce reductions.

What preclinical results did Editas (EDIT) announce for EDIT-401?

EDIT-401 demonstrated greater than 90% mean LDL-C reduction in non-human primate studies in preclinical testing. According to the company, additional preclinical data will be presented by mid-2026 as development progresses toward an IND/CTA.

What material charges affected Editas (EDIT) in 2025 and why?

Restructuring and impairment charges increased to $60.7 million in 2025, driven by program discontinuation and workforce reductions. According to the company, these charges reflect actions related to ending the former reni-cel program and associated contract and staffing adjustments.